南新制药因子公司虚增营收被罚 2020上市西部证券保荐

Core Viewpoint - The Ministry of Finance of China has issued administrative penalties against Hunan Nanxin Pharmaceutical Co., Ltd. for accounting irregularities, including the overstatement of revenue and costs, as well as fraudulent academic promotion expenses [1][2][3]. Group 1: Accounting Irregularities - Nanxin Pharmaceutical's subsidiary, Guangzhou Nanxin Pharmaceutical Co., Ltd., recognized 2023 revenue of 28,296,301.07 yuan and cost of goods sold of 4,412,163.38 yuan based on falsified shipping documents [2][6]. - The company overstated 2023 revenue by 24,539,733.46 yuan and costs by 3,839,043.33 yuan due to discrepancies in shipping and customer acceptance processes [2][14]. - The company was found to have used identical promotional activity photos across different regions and had discrepancies in signatures of attendees, indicating fraudulent reporting of academic promotion expenses totaling 37,000,000.00 yuan [3][11]. Group 2: Penalties Imposed - The Ministry of Finance imposed a fine of 100,000 yuan on Nanxin Pharmaceutical for the accounting violations [3][8]. - Zhang Shixi, the company’s responsible unit head, was fined 50,000 yuan for his role in the violations [3][12]. - Li Liang, the head of accounting, received a fine of 30,000 yuan for his responsibility in the accounting issues [3][15]. Group 3: Company Background - Nanxin Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 26, 2020, with an initial offering price of 34.94 yuan per share and raised a total of 1.223 billion yuan [4][6]. - The company has undergone multiple capital increases, including a stock dividend distribution that increased its total share capital from 140 million to 196 million shares in 2022, and further to 274.4 million shares in 2023 [5][6].